AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 10 - (NewsRx.com & NewsRx.net) -- Researchers have demonstrated that CD8(+) T-cell response was markedly improved when stabilized liposomes are used to deliver proteins to dendritic cells.
They propose that this method of antigen delivery is safe and effective for CD4/CD8(+) T-cell-inducing vaccines.
"Liposomes have been proposed as a vehicle to deliver proteins to antigen-presenting cells (APC), such as dendritic cells (DC), to stimulate strong T-cell-mediated immune responses. Unfortunately, because of their instability in vivo and their rapid uptake by cells of the mononuclear phagocyte system on intravenous administration, most types of conventional liposomes lack clinical applicability," wrote R. Ignatius and colleagues at Rockefeller University's Aaron Diamond AIDS Research Center. "In contrast, sterically stabilized liposomes (SL) have increased in vivo stability."
In in vitro experiments, Ignatius et al. found that dendritic cells, both at immature and mature stages, "take up SL into neutral or mildly acidic compartments distinct from endocytic vacuoles."
When ovalbumin encapsulated in SL was presented to T cells, the researchers reported that CD8(+) T-cell response was up to 300 greater than that produced when the cells were presented with soluble protein.
CD4(+) T-cell response, they said, was similar to that induced by soluble protein.
"DC processed SL-encapsulated antigen through a TAP-dependent mechanism," added Ignatius et al. ("Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in ...
Source: HighBeam Research, Proteins Encapsulated in Stabilized Liposomes Produce Safe, Effective...